Study on Inhaled Fluticasone and Salmeterol for COPD
Author Information
Author(s): Sin Don D, Man SF Paul, Marciniuk Darcy D, Ford Gordon, FitzGerald Mark, Wong Eric, York Ernest, Mainra Rajesh R, Ramesh Warren, Melenka Lyle S, Wilde Eric, Cowie Robert L, Williams Dave, Rousseau Roxanne
Primary Institution: University of British Columbia
Hypothesis
Can inhaled fluticasone alone or in combination with salmeterol reduce systemic inflammation in chronic obstructive pulmonary disease?
Conclusion
The study aims to determine if inhaled corticosteroids can reduce systemic inflammation and improve health status in COPD patients.
Supporting Evidence
- Systemic inflammation is linked to various complications in COPD.
- Inhaled corticosteroids can reduce airway inflammation and improve mortality in COPD.
- The study will assess the effects of inhaled corticosteroids on systemic inflammation.
Takeaway
This study is trying to find out if a medicine called fluticasone, alone or with another medicine called salmeterol, can help people with breathing problems feel better and be healthier.
Methodology
The study is a double-blind, placebo-controlled trial with a run-in phase followed by randomization to fluticasone, combination therapy, or placebo.
Potential Biases
Potential bias from the funding source, GlaxoSmithKline, though they will not have access to raw data.
Limitations
The study will not measure inflammation in the lungs and has a relatively short follow-up period.
Participant Demographics
Participants must be 40 years or older with a smoking history of at least 10 pack-years and diagnosed with COPD.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website